GE HealthCare is a top-3 global medical imaging oligopolist with a $21.8B record backlog, transitioning from a hardware-centric model to an AI-enabled, recurring-revenue platform through Photonova Spectra (photon-counting CT, FDA cleared March 2026), Flyrcado (first-of-kind PET radiotracer targeting $500M by 2028), Intelerad ($2.3B cloud imaging acquisition), and the Genesis cloud-first radiology workspace. The installed base generates high-margin service revenue (~40%+ of sales) with multi-year switching costs, while Pharmaceutical Diagnostics is the fastest-growing segment at 15.6% YoY. Tariff headwinds (~$0.85/share in 2026) are a near-term overhang but manageable through supply chain optimization.
| Scenario | Prob. | Target | Driver |
|---|---|---|---|
| Bull | 25% | $100.00 | Photonova Spectra generates $300M+ orders in first 12 months — validates PCCT product cycle |
| Base | 50% | $84.00 | FY2026 delivers within guided range: organic growth 3-4%, adjusted EPS $4.95-$5.15 |
| Bear | 25% | $56.00 | Tariff escalation: >$1.00/share EPS headwind if new tariffs imposed or USMCA mitigation fails |
Initial coverage — Photonova FDA clearance + tariff impact assessment
None mapped.
Positioning skews toward near-term upside